Economic burden of renal cell carcinoma in the US: Part II an updated analysis

PharmacoEconomics

Volumn 29, Issue 4, 2011, Pages 331-341

  Shih, Ya Chen T ^a   Chien, Chun Ru ^b   Xu, Ying ^a   Pan, I Wen ^a   Smith, Grace L ^a   Buchholz, Thomas A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Cost of illness; Renal cell carcinoma; Sorafenib; Sunitinib; therapeutic use; treatment

Indexed keywords

BEVACIZUMAB; RITUXIMAB; SORAFENIB; SUNITINIB;

ARTICLE; COST OF ILLNESS; COST UTILITY ANALYSIS; HUMAN; KIDNEY CANCER; KIDNEY CARCINOMA; MEDICARE; PRIORITY JOURNAL;

AGED; AGED, 80 AND OVER; CARCINOMA, RENAL CELL; DATABASES, FACTUAL; FEES AND CHARGES; FEMALE; HEALTH EXPENDITURES; HUMANS; MALE; MEDICARE; UNITED STATES;

EID: 79952643126     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.2165/11586110-000000000-00000     Document Type: Article

References (19)

1. Shih Y-CT, Chien C-R, Xu Y, et al. Economic burden of renal cell carcinoma. Part I-an updated review. Pharma-coeconomics 2011; 29 (4): 315-29
2. Wallen EM, Pruthi RS, Joyce GF, et al. Kidney cancer. J Urol 2007 Jun; 177 (6): 2006-18; discussion 18-9
3. Lang K, Danchenko N, Gondek K, et al. The burden of illness associated with renal cell carcinoma in the United States. Urol Oncol 2007 Sep-Oct; 25 (5): 368-75 (Pubitemid 47362759)
4. Yabroff KR, Davis WW, Lamont EB, et al. Patient time costs associated with cancer care. J Natl Cancer Inst 2007 Jan 3; 99 (1): 14-23
5. Yabroff KR, Lamont EB, Mariotto A, et al. Cost of care for elderly cancer patients in the United States. J Natl Cancer Inst 2008 May 7; 100 (9): 630-41
6. Warren JL, Klabunde CN, Schrag D, et al. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care 2002 Aug; 40 (8 Suppl.): IV-3-18
7. Medstat. Market Scan Research Databases user guide and database dictionary: multi-state Medicaid database 1999-2005 edition. Ann Arbor (MI): Medstat, 2007
8. SEER. Training for the multiple primary and histology coding rules [online]. Available from URL: http://seer.cancer. gov/tools/mphrules/training. html [Accessed 2009 Dec 12]
9. Brown ML, Riley GF, Schussler N, et al. Estimating health care costs related to cancer treatment from SEER-Medi-care data. Med Care 2002 Aug; 40 (8 Suppl.): IV-104-17
10. Karon JM, Kupper LL. In defense ofmatching. Am J Epi-demiol 1982 Nov; 116 (5): 852-66
11. Kupper LL, Karon JM, Kleinbaum DG, et al. Matching in epidemiologic studies: validity and efficiency considera-tions. Biometrics 1981 Jun; 37 (2): 271-91
12. Barber JA, Thompson SG. Analysis of cost data in randomized trials: an application of the non-parametric bootstrap. Stat Med 2000 Dec 15; 19 (23): 3219-36
13. Basu A. Extended generalized linear models: simultaneous estimation of flexible link and variance functions. Stata J 2005; 5 (4): 501-16 (Pubitemid 43708455)
14. Basu A, Rathouz PJ. Estimating marginal and incremental effects on health outcomes using flexible link and variance function models. Biostatistics 2005; 6 (1): 93-109 (Pubitemid 41240372)
15. Klabunde CN, Legler JM, Warren JL, et al. A refined comorbidity measurement algorithm for claims-based studies of breast, prostate, colorectal, and lung cancer patients. Ann Epidemiol 2007 Aug; 17 (8): 584-90 (Pubitemid 47096709)
16. Klabunde CN, Potosky AL, Legler JM, et al. Development of a comorbidity index using physician claims data. J Clin Epidemiol 2000 Dec; 53 (12): 1258-67 (Pubitemid 32007842)
17. Duh MS, Dial E, Choueiri TK, et al. Costimplicationsof IV versus oral anti-angiogenesis therapies in patients with ad-vanced renal cell carcinoma: retrospective claims database analysis. Curr Med Res Opin 2009 Aug; 25 (8): 2081-90
18. Amato RJ, Shingler W, Naylor S, et al. Vaccination ofrenal cell cancer patients with modified vaccinia ankara deliver-ing tumor antigen 5T4 (TroVax) administered with inter-leukin 2: a phase II trial. Clin Cancer Res 2008 Nov 15; 14 (22): 7504-10
19. Hawkins RE, Macdermott C, Shablak A, et al. Vaccination of patients with metastatic renal cancer with modified vaccinia ankara encoding the tumor antigen 5T4 (TroVax) given alongside interferon-alpha. J Immunother 2009 May; 32 (4): 424-9